Encephalopathy cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Encephalopathy in its very early stages is cost effective. Early intervention relieves forthcoming complications and the costs that would have come along with them. | |||
==Financial Costs== | ==Financial Costs== | ||
* Cost effectiveness of various therapies depends on the condition. | * Cost effectiveness of various therapies depends on the condition. | ||
* Hypothermia | * [[Hypothermia]] for [[neonatal encephalopathy]] - The incremental cost per disability-free life year gained was $28,124 (£19,931 ; €26,920) as per the data of 2006 Organisation for Economic Co-operation and Development (OECD). <ref name="pmid20561343">{{cite journal |author=Regier DA, Petrou S, Henderson J, ''et al.'' |title=Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy |journal=Value Health |volume=13 |issue=6 |pages=695–702 |year=2010 |pmid=20561343 |doi=10.1111/j.1524-4733.2010.00731.x |url=}}</ref> | ||
* Detection of minimal hepatic encephalopathy, especially using the inhibitory control test, and subsequent treatment with [[lactulose]] could substantially reduce societal costs by preventing motor vehicle accident. Net program savings over 5 years ranged from $1.7 to 3.6 million.<ref name="pmid22135042">{{cite journal |author=Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM |title=Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis |journal=Hepatology |volume=55 |issue=4 |pages=1164–71 |year=2012 |month=April |pmid=22135042 |doi=10.1002/hep.25507 |url=}}</ref> | * Detection of minimal hepatic encephalopathy, especially using the inhibitory control test, and subsequent treatment with [[lactulose]] could substantially reduce societal costs by preventing motor vehicle accident. Net program savings over 5 years ranged from $1.7 to 3.6 million.<ref name="pmid22135042">{{cite journal |author=Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM |title=Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis |journal=Hepatology |volume=55 |issue=4 |pages=1164–71 |year=2012 |month=April |pmid=22135042 |doi=10.1002/hep.25507 |url=}}</ref> | ||
| Line 15: | Line 15: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 20:31, 27 July 2012
|
Encephalopathy |
|
Diagnosis |
|---|
|
Treatment |
|
Encephalopathy cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Encephalopathy cost-effectiveness of therapy |
|
Risk calculators and risk factors for Encephalopathy cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Encephalopathy in its very early stages is cost effective. Early intervention relieves forthcoming complications and the costs that would have come along with them.
Financial Costs
- Cost effectiveness of various therapies depends on the condition.
- Hypothermia for neonatal encephalopathy - The incremental cost per disability-free life year gained was $28,124 (£19,931 ; €26,920) as per the data of 2006 Organisation for Economic Co-operation and Development (OECD). [1]
- Detection of minimal hepatic encephalopathy, especially using the inhibitory control test, and subsequent treatment with lactulose could substantially reduce societal costs by preventing motor vehicle accident. Net program savings over 5 years ranged from $1.7 to 3.6 million.[2]
References
- ↑ Regier DA, Petrou S, Henderson J; et al. (2010). "Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy". Value Health. 13 (6): 695–702. doi:10.1111/j.1524-4733.2010.00731.x. PMID 20561343.
- ↑ Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM (2012). "Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis". Hepatology. 55 (4): 1164–71. doi:10.1002/hep.25507. PMID 22135042. Unknown parameter
|month=ignored (help)